Articles

India's Pharma Industry Goes Global: Can It Compete with China?

India's pharmaceutical sector is expanding internationally, but the question remains: can it rival China's dominance? This article explores the implications for the industry.

NICE Backs Imfinzi for Stomach Cancer: Implications for Investors

NICE's recent approval of Imfinzi for stomach cancer marks a significant milestone for AstraZeneca. This article explores the implications for investors and pharma teams.

Roche's ctDNA-Guided Approach in Bladder Cancer: A Strategic Win

Roche's innovative ctDNA-guided approach for Tecentriq in post-surgical bladder cancer has garnered significant attention. This article explores the implications for pharmaceutical teams and investors.

WHO Declares Ebola Outbreak an International Emergency

The WHO has declared the Ebola outbreak an international public health emergency, prompting critical responses from the pharmaceutical sector. This article explores the implications for business and investment.

ASCO 2026 Oncology Drug Pipeline Preview

Get an in-depth preview of the ASCO 2026 oncology drug pipeline, focusing on key presentations from leading pharma companies and their competitive positioning.

FDA Approves Eli Lilly's Zepbound for Obstructive Sleep Apnea

Eli Lilly's tirzepatide, branded as Zepbound, receives FDA approval for obstructive sleep apnea, marking a significant milestone in treatment options. This approval could reshape the competitive landscape and expand the GLP-1 class market.

BIO 2026 Preview: Companies to Watch and Key Catalysts

Get insights into the companies to watch and key catalysts for business development teams at the BIO International Convention 2026.

FDA Approval for Pfizer's Breast Cancer Drug: Vepdegestrant

The FDA has granted approval for Pfizer and Arvinas' novel breast cancer drug, vepdegestrant. This marks a significant new treatment option for patients with advanced or metastatic HR-positive, HER2-negative breast cancer who have exhausted prior endocrine therapies.

Auvelity FDA Approval: New MDD Treatment Option

The FDA has approved Auvelity, a new oral treatment for major depressive disorder (MDD) in adults, marking a significant advancement in mental health therapeutics. Manufactured by Axsome Therapeutics, this approval offers a novel option for patients seeking relief from MDD.

FDA Scrutiny Post-Market Data: Impact on Pharma Investment Strategies

This article examines the implications of FDA scrutiny on post-market data and its influence on pharmaceutical investment strategies and drug development.

Inflation Reduction Act Pharmaceutical Impact: What You Need to Know

Learn about the Inflation Reduction Act's effects on pharmaceutical pricing, focusing on key medications like insulin and cancer therapies for Medicare patients.

ANVISA Clinical Trial Changes Brazil: What You Need to Know

Learn about the recent changes to ANVISA's clinical trial regulations in Brazil and how they impact drug development for various medical indications.

ANVISA Regulatory Changes: Key Impact on Foreign Drug Manufacturers in Brazil

ANVISA's recent regulatory changes significantly affect foreign drug manufacturers in Brazil, influencing drug approvals and market strategies for key treatments.

SAHPRA Accelerated Approval: What You Need to Know About Oncology Access

Learn how SAHPRA's Accelerated Approval is transforming oncology access, expediting vital treatments like Pembrolizumab for cancer patients in need.

African Medicines Agency impact: Harmonizing Clinical Trials in Africa

The African Medicines Agency is transforming clinical trials in Africa, streamlining processes for drug approvals and improving access to essential medicines.

Local Pharmaceutical Manufacturing South Africa: SAHPRA Policy Impact 2025

This article examines the implications of SAHPRA's 2025 policies on local pharmaceutical manufacturing in South Africa, focusing on drug accessibility and innovation.

FDA Accelerated Approval Pathway: Impact on Oncology Market Access & Pricing in 2026

This article examines how the FDA's Accelerated Approval Pathway will shape oncology market access and pricing strategies for cancer therapies in 2026.

FDA Guidance on Oncology Drugs: New Rules for Accelerated Approval

The FDA's new guidance on oncology drugs outlines updated rules for accelerated approval, impacting treatments such as Pembrolizumab for various cancers.

ANVISA Approves New Cannabis Framework & MagicTouch Device: Market Impact

The recent ANVISA approval of a new cannabis framework and the MagicTouch device marks a significant advancement in pain management solutions in Brazil.

COFEPRIS Drug Approvals 2026: What You Need to Know

Stay informed about COFEPRIS drug approvals in 2026, featuring essential insights on innovative treatments for diabetes and hypertension.